Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Glycididazole in Esophageal Squamous Carcinoma
NCT00642239Phase 4Unknown
- Sponsor
- Luye Pharma Group
- Start
- Apr 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Sodium Glycididazole Arm with Placebo Arm (2 arms). Primary endpoint: Tumour Local Control Rate at 6 weeks. Status: unknown.
02
Drugs
sodium glycididazole
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT00642239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642239.